[1] BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA-Cancer J Clin,2018, 68(6):394-424. [2] TRAVIS W D, BRAMBILLA E, NOGUCHI M, et al. International association for the study of lung cancer/American thoracic society/European respiratory society international multidisciplinary classification of lung adenocarcinoma[J]. J Thorac Oncol, 2011,6(2):244-285. [3] CASALI C, ROSSI G, MARCHIONI A, et al. A single institution-based retrospective study of surgically treated bronchioloalveolar adenocarcinoma of the lung:clinicopathologic analysis, molecular features, and possible pitfalls in routine practice[J]. J Thorac Oncol,2010,5(6):830-836. [4] CHA M J, LEE K S, KIM T J, et al. Solitary nodular invasive mucinous adenocarcinoma of the lung:imaging diagnosis using the morphologic-metabolic dissociation sign[J]. Korean J Radiol, 2019,20(3):513-521. [5] 马洪波,周琪,张献全.非小细胞肺癌非EGFR驱动基因与靶向治疗研究进展[J].现代医药卫生,2018,34(20):3180-3183. [6] OU S H, AHN J S, De PETRIS L, et al. Alectinib in crizotinib-refractory alk-rearranged non-small-cell lung cancer:a phase II global study[J]. J Clin Oncol,2016,34(7):661-668. [7] MARCHETTI A, BUTTITTA F, PELLEGRINI S, et al. Bronchioloalveolar lung carcinomas:K-ras mutations are constant events in the mucinous subtype[J]. J Pathol,1996, 179(3):254-259. [8] HIGASHIYAMA M, DOI O, KODAMA K, et al. Cystic mucinous adenocarcinoma of the lung, two cases of cystic variant of mucus-producing lung adenocarcinoma[J]. Chest,1992, 101(3):763-766. [9] SHIM H S, MARI-KENUDSON, ZHENG Z L, et al. Unique genetic and survival characteristics of invasive mucinous adenocarcinoma of the lung[J]. J Thorac Oncol,2015,10(8):1156-1162. [10] 王红辉,刘婉洁,张翔辰,等.肺粘液腺癌1例报道[J].影像研究与医学应用,2018,2(15):164-165. [11] LEE H Y, CHA M J, LEE K S, et al. Prognosis in resected invasive mucinous adenocarcinomas of the lung:related factors and comparison with resected nonmucinous adenocarcinomas[J]. J Thorac Oncol,2016, 11(7):1064-1073. [12] WATANABE H, SAITO H, YOKOSE T, et al. Relation between thin-section computed tomography and clinical findings of mucinous adenocarcinoma[J]. Ann Thorac Surg,2015,99(3):975-981. [13] LIN J J, CARDARELLA S, LYDON C A, et al. Five year survival in egfr-mutant metastatic lung adenocarcinoma treated with egfr-tkis[J]. J Thorac Oncol,2016,11(4):556-565. [14] KADOTA K, YEH Y C, D'ANGELO S P, et al. Associations between mutations and histologic patterns of mucin in lung adenocarcinoma:invasive mucinous pattern and extracellular mucin are associated with kras mutation[J]. Am J Surg Pathol,2014,38(8):1118-1127. [15] ADDERLEY H, BLACKHALL F H, LINDSAY C R. KRAS-mutant non-small cell lung cancer:Converging small molecules and immune checkpoint inhibition[J]. EBioMedicine,2019,41:711-716. [16] DONG Z Y, ZHONG W Z, ZHANG X C, et al. Potential predictive value of TP53 and KRAS mutation status for response to PD-1 blockade immunotherapy in lung adenocarcinoma[J]. Clin Cancer Res,2017,23(12):3012-3024. [17] HELLMANN M D, NATHANSON T, RIZVI H, et al. Genomic features of response to combination immunotherapy in patients with advanced non-small-cell lung cancer[J].Cancer Cell, 2018,33(5):843-852. [18] 李涛,张娟,胡毅.复合型小细胞肺癌研究进展[J].解放军医学杂志,2018,43(9):799-805. [19] 支修益,吴一龙,马胜林,等.原发性肺癌诊疗规范(2011年版)[J].中国肺癌杂志,2012,15(12):677-688. |